PSP Research LLC Buys Shares of 10,758 Supernus Pharmaceuticals, Inc. $SUPN

PSP Research LLC bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,758 shares of the specialty pharmaceutical company’s stock, valued at approximately $535,000.

Other large investors have also modified their holdings of the company. Hantz Financial Services Inc. boosted its position in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares during the period. Torren Management LLC purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $49,000. Smartleaf Asset Management LLC boosted its position in shares of Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 268 shares during the period. Vestcor Inc purchased a new position in shares of Supernus Pharmaceuticals during the third quarter valued at approximately $67,000. Finally, State of Wyoming purchased a new position in shares of Supernus Pharmaceuticals during the third quarter valued at approximately $68,000.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of “Hold” and a consensus price target of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In other news, Director Frederick M. Hudson sold 5,369 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the sale, the director directly owned 60,413 shares of the company’s stock, valued at $3,057,501.93. This represents a 8.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jack A. Khattar sold 35,000 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the sale, the chief executive officer directly owned 958,100 shares in the company, valued at approximately $48,259,497. The trade was a 3.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 120,881 shares of company stock worth $6,139,356 over the last 90 days. Insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Trading Down 1.5%

Shares of SUPN stock opened at $47.62 on Wednesday. The business’s fifty day simple moving average is $50.29 and its 200-day simple moving average is $49.79. The company has a market cap of $2.76 billion, a PE ratio of -93.37, a PEG ratio of 1.04 and a beta of 0.57. Supernus Pharmaceuticals, Inc. has a 12-month low of $30.83 and a 12-month high of $59.68.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.